Sporotrichosis

Summary

Sporotrichosis (MONDO:0005968) is a disease and 5 clinical trials. Top therapeutic interventions include fluconazole, itraconazole, and hyoscyamine. A subtype of fungal infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 5

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-5 / 10 000	54	Peru	Validated
Point prevalence	>1 / 1000	2500	Mexico	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	sporotrichosis
Mondo ID	MONDO:0005968
EFO	EFO:0007494
MeSH	D013174
Orphanet	826
DOID	DOID:14484
ICD-10-CM	B42
ICD-11	579570784
SNOMED CT	42094007
UMLS	C0038034
MedGen	21298
GARD	0007692
MedDRA	10041736
Is cancer (heuristic)	no

Also known as: rose gardener’s disease

Disease family

This is a subtype of fungal infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › sporotrichosis

Related subtypes (17): cutaneous mycosis, systemic mycosis, fungal esophagitis, opportunistic mycosis, fungal gastritis, fungal lung infectious disease, Pneumocystis infectious disease, fungal meningitis, fungal myositis, scedosporiosis, fungal infection of eye, mycotic endocarditis, mycotoxicosis, alternariosis, invasive scopulariopsis infection, emergomycosis, fungal discitis

Subtypes (1): disseminated sporotrichosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Amphotericin B	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Fluconazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004808	PHASE2	COMPLETED	Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
NCT00004811	PHASE1/PHASE2	COMPLETED	Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis
NCT00004938	PHASE2	COMPLETED	Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
NCT06300138	Not specified	RECRUITING	Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis
NCT06523998	Not specified	COMPLETED	A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUCONAZOLE	4	2
ITRACONAZOLE	4	1
HYOSCYAMINE	-1	1